In this issue of Blood, Pemmaraju et al 1 identify, through TRANSFORM-1, both the promise and limits of combining navitoclax with ruxolitinib, sharpening a central challenge in myelofibrosis (MF) drug development: how best to measure meaningful clinical benefit.
No takes yet. Share an insight, caveat, or question.
Vachhani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: